Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16271388 | 0.85 | GRIA4 (0.42) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| SCHEMBL13784925 | 0.82 | CA2 (0.47) | ALDH1A1CA1CA2 | |
| SCHEMBL6537145 | 0.79 | SHBG (0.59) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| SCHEMBL4733508 | 0.79 | LMNA (0.45) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| SCHEMBL19990147 | 0.79 | LMNA (0.35) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| SCHEMBL19999723 | 0.79 | LMNA (0.35) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28138846 | 0.78 | LMNA (0.43) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| SCHEMBL27251087 | 0.76 | LMNA (0.45) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| SCHEMBL20026776 | 0.74 | LMNA (0.34) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 | |
| SCHEMBL196750 | 0.74 | ALDH1A1 (0.61) | LMNAALDH1A1TSHRNT5ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295457-A1 | SURFACE TREATMENT LIQUID AND SURFACE TREATMENT METHOD | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20210210701-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210063888-A1 | METHOD FOR FORMING PATTERNED PHOTORESIST | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210210701-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OSBP, OSBPL3, OCIAD2 | LMNA 4653/4885ALDH1A1 2813/4885TSHR 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.